Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Net Margin (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Net Margin data on record, last reported at 1988.48% in Q4 2025.

  • For Q4 2025, Net Margin changed N/A year-over-year to 1988.48%; the TTM value through Dec 2025 reached 6039.88%, up 2258919.0%, while the annual FY2025 figure was 6046.22%, 2262924.0% up from the prior year.
  • Net Margin reached 1988.48% in Q4 2025 per CRNX's latest filing, up from 90972.73% in the prior quarter.
  • Across five years, Net Margin topped out at 1074.23% in Q1 2022 and bottomed at 90972.73% in Q3 2025.
  • Average Net Margin over 5 years is 15155.22%, with a median of 9400.75% recorded in 2022.
  • The widest YoY moves for Net Margin: up 733895bps in 2025, down -1640581bps in 2025.
  • A 5-year view of Net Margin shows it stood at 2857.88% in 2021, then tumbled by -125bps to 6438.93% in 2022, then tumbled by -153bps to 16302.89% in 2023, then decreased by -14bps to 18556.89% in 2024, then surged by 89bps to 1988.48% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 1988.48% in Q4 2025, 90972.73% in Q3 2025, and 11217.94% in Q2 2025.